Gene · 8065
CUL5: cullin 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CUL5: cullin 5. Genes, record 8065. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8065
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q93034 | Cullin-5 | 780 | 15 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 42560 | Q93034 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 42561 | Q93034 | Espacenet |
| WO 2025239292 A | 2025-11-20 | 1 | Q93034 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 10991 | Q93034 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 11403 | Q93034 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 11403 | Q93034 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10991 | Q93034 | Espacenet |
| EP 4253412 A2 | 2023-10-04 | 16 | Q93034 | Espacenet |
| US 11492404 B2 | 2022-11-08 | 16 | Q93034 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 20798 | Q93034 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,232
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CUL5 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 17 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 11 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 8 | 2025 |
| T32AI083196 | Minnesota Training Program in Virology | 6 | 2025 |
| ZIAAI000669 | Molecular Analysis Of Retroviral Genes And Their Products | 6 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 5 | 2025 |
| R01GM122768 | The mechanisms regulating actin dynamics and polarized membrane transport during cell migration | 5 | 2025 |
| T32AI060537 | Integrative Microbiology Program | 5 | 2025 |
| ZIABC010595 | Structure and Function of Vif and APOBEC3 (A3) Proteins | 5 | 2025 |
| U19AI135990 | HPMI: Host Pathogen Mapping Initiative | 4 | 2025 |
1 to 10 of 1,232Source NIH's project files
See all 1,232 nih grantsPapers1,704
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Inhibition of nucleoporin 214 depletes leukemia stem cells by promoting heme catabolism and lipid peroxidation. | Blood | 2026 | 42640860 | PubTator, text mining | PubMed |
| Neddylation-dependent RAB40-Cullin5 E3 ligase complex controls ubiquitin-mediated proteasomal degradation of DNAJC13. | BBA Adv | 2026 | 42602476 | PubTator, text mining | PubMed |
| Discovery of spirocyclic amide scaffolds as novel neddylation E1 inhibitors to suppress the growth and survival of lung cancer cells. | RSC Med Chem | 2026 | 42559520 | PubTator, text mining | PubMed |
| A de novo designed enzyme for photo-proximity labeling of E3 ligase neighborhoods in live cells. | bioRxiv | 2026 | 42538903 | PubTator, text mining | PubMed |
| Structure of the E3 ligase CRL2ZYG11B with substrates reveals the molecular basis for N-degron recognition and ubiquitination. | Cell Rep | 2026 | 42224082 | PubTator, text mining | PubMed |
| Targeting UBE2F induces a resilience program enhancing CD8 T cell immunity. | J Exp Med | 2026 | 42188874 | PubTator, text mining | PubMed |
| Cysteine availability tunes ubiquitin signaling via inverse stability of LRRC58 E3 ligase and its substrate CDO1. | Nat Commun | 2026 | 42098103 | PubTator, text mining | PubMed |
| ASB7 promotes osteosarcoma lung metastasis through ubiquitin-mediated degradation of ATF2. | Cell Discov | 2026 | 42086529 | PubTator, text mining | PubMed |
| CUL5-mediated ubiquitination in cancer cell therapy: context-dependent roles, molecular networks, and emerging therapeutic avenues. | Front Med (Lausanne) | 2026 | 42078440 | PubTator, text mining | PubMed |
| In silico analysis of gene expression signatures and drug repurposing associated with metastatic progression in melanoma (skin cancer). | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42068380 | PubTator, text mining | PubMed |
1 to 10 of 1,704
See all 1,704 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8065
GET https://conductscience.org/api/genes/v1/8065/patents?page=2